When was Compass Therapeutics founded?

Compass Therapeutics was founded in 2013.

Where is Compass Therapeutics located?

Compass Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Compass Therapeutics?

Thomas Schuetz of Compass Therapeutics.

How many employees does Compass Therapeutics have?

As of Jun 30, 2026, the latest employee count at Compass Therapeutics is 58.

Is Compass Therapeutics a funded company?

Compass Therapeutics is a funded company, having raised a total of $239M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of Compass Therapeutics?

Compass Therapeutics' latest funding was a $***** Series A round on Jun 23, 2020, with participation from 9 investors.

What is the annual revenue of Compass Therapeutics?

Annual revenue of Compass Therapeutics is less than $1M as on Dec 31, 2024

Where does Compass Therapeutics rank among its competitors?

Compass Therapeutics ranks 51st amongst 3309 active competitors, of which 1130 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Compass Therapeutics?

Compass Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Compass Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Compass Therapeutics is a public company based in Cambridge (United States), founded in 2013 by Thomas Schuetz. It operates as an Antibody discovery and development company. Compass Therapeutics has raised $239M in funding from Orbimed and Consonance Capital. The company has 3309 active competitors, including 1130 funded and 779 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Compass Therapeutics develops and discovers therapeutic antibodies for cancer treatment. The company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonal, and engineered protein constructs.

Website: www.compasstherapeutics.com/
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2013

Location

Cambridge, United States

Stage

Public

Total Funding

$239M in 7 rounds

Latest Funding Round

Series A, Jun 23, 2020, $*****

Investors

Orbimed & 18 more

Ranked

51^st among 3309 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

58 as on Jun 30, 2026

Investment & Acquisitions

TRIGR Therapeutics

Similar Companies

Jazz Pharmaceuticals & 3045 more

Exit Details

Public

View Compass Therapeutics' full profile

Compass Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
COMPASS THERAPEUTICS ADVISORS, INC. CIN: 473107062 , United States, Active	Dec 31, 1999	-	34 (As on Dec 31, 2024)	-
COMPASS THERAPEUTICS, INC. CIN: 1738021 , United States, Active	Mar 19, 2018	$0 - $1M (As on Dec 31, 2024)	-	-

Compass Therapeutics got listed on Apr 05, 2021.

Click here to take a look at Compass Therapeutics's IPO in detail

Compass Therapeutics has raised a total funding of $239M over 7 rounds. Its latest funding round was a Series A round on Jun 23, 2020 for $*****. 9 investors participated in its latest round. Compass Therapeutics has 18 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Compass Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 23, 2020	2017172	Series A	1690547	9923849	6840766	8860955
Jul 12, 2018	7810225	Series A	4045046	8111988	7108473	F-Prime Capital & 7 more
Sep 21, 2016	6409227	Series A	9104032	4213222	3365261	Orbimed & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Compass Therapeutics's funding rounds and investors

The founders of Compass Therapeutics is Thomas Schuetz.

Here are the details of Compass Therapeutics' key team members:

Thomas Schuetz: Co-Founder & CEO of Compass Therapeutics.

View details of Compass Therapeutics's Founder profiles and Board Members

Compass Therapeutics' employee count trend

Compass Therapeutics has 58 employees as of Jun 26. Here is Compass Therapeutics's employee count trend over the years:

Employee count trend for Compass Therapeutics

Uncover Compass Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Compass Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Compass Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
51st	Compass Therapeutics 2013, Cambridge (United States), Public	Antibody discovery and development company	$239M	Foresite Capital, Google Ventures & 17 others	65/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Compass Therapeutics's competitors? Click here to see the top ones

Compass Therapeutics has acquired TRIGR Therapeutics. Compass Therapeutics has not made any investments as of now.

Here is the latest report on Compass Therapeutics's geography:

Free

US Tech Semi Annual Funding Report

Edition: H1, 2026 (47 Pages)

View all reports related to Compass Therapeutics

Media has covered Compass Therapeutics for a total of 17 events in the last 1 year, 12 of them have been about company updates and 2 about people movement.